Elevated serum (AP may serve as an independent indicator of DPN in individuals with type 2 diabetes mellitus (T2DM). A study published in Frontiers in Endocrinology found that integrating AP into routine assessments improved identification of patients at neuropathy risk.

The cross-sectional study included 476 adults with T2DM. DPN was confirmed using the Toronto Clinical Neuropathy Score (TCNS) and nerve conduction studies. Associations were examined through multivariable logistic regression, and restricted cubic spline (RCS) modelling was used to assess non-linear risk relationships. Predictive capability was evaluated using receiver operating characteristic (ROC) curve analysis.

Serum AP levels were significantly higher in patients with DPN than in those without (P<0.001). After adjustment for clinical confounders, elevated AP remained an independent indicator of DPN (odds ratio 1.024; 95% CI 1.012–1.036). RCS analysis identified a marked inflection point at 119.628 µm², above which DPN risk increased substantially. Diagnostic accuracy improved when AP was combined with clinical factors, increasing the area under the curve from 0.686 to 0.805.

These findings suggest that AP measurement could support earlier recognition of DPN in T2DM and strengthen clinical risk evaluation when added to standard assessments.